Active domestication of the Korean contrast agent market worth of KRW 200 billion…and entry of Ilsung Pharmaceuticals
As domestically developed products have entered in the contrast agent market, worth of KRW 200 billion currently led by Bayer Healthcare and GE Healthcare, the industry has paid attention in the dynamics of the market.
While Pamiray (Iopamidol) launched by Dongkook Pharmaceutical has established...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
